6FN Stock Overview
Operates as a pharmaceutical company. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Klaria Pharma Holding AB (publ.) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.027 |
| 52 Week High | SEK 0.076 |
| 52 Week Low | SEK 0.01 |
| Beta | 0.44 |
| 11 Month Change | -49.06% |
| 3 Month Change | -24.02% |
| 1 Year Change | 10.57% |
| 33 Year Change | -95.61% |
| 5 Year Change | n/a |
| Change since IPO | -95.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6FN | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -22.3% | -1.2% | -0.02% |
| 1Y | 10.6% | -20.1% | 8.2% |
Return vs Industry: 6FN exceeded the German Pharmaceuticals industry which returned -20.1% over the past year.
Return vs Market: 6FN exceeded the German Market which returned 8.2% over the past year.
Price Volatility
| 6FN volatility | |
|---|---|
| 6FN Average Weekly Movement | 28.5% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6FN's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6FN's weekly volatility has decreased from 37% to 29% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 5 | Scott Boyer | www.klaria.com |
Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company. It develops Sumatriptan for the treatment of migraine. The company also develops Epinephrine/Adrenaline, which is in Phase I clinical trial for the treatment of acute allergic reaction.
Klaria Pharma Holding AB (publ.) Fundamentals Summary
| 6FN fundamental statistics | |
|---|---|
| Market cap | €5.00m |
| Earnings (TTM) | -€3.62m |
| Revenue (TTM) | n/a |
-7.8x
P/S Ratio-1.4x
P/E RatioIs 6FN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6FN income statement (TTM) | |
|---|---|
| Revenue | -SEK 7.38m |
| Cost of Revenue | SEK 0 |
| Gross Profit | -SEK 7.38m |
| Other Expenses | SEK 34.26m |
| Earnings | -SEK 41.64m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 21, 2025
| Earnings per share (EPS) | -0.29 |
| Gross Margin | 100.00% |
| Net Profit Margin | 564.53% |
| Debt/Equity Ratio | 0% |
How did 6FN perform over the long term?
See historical performance and comparison